Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Dementia  (3)
  • clinical trials  (2)
  • Antidepressants  (1)
  • 1
    ISSN: 1364-6753
    Keywords: Key words Alzheimer disease ; Amyloid plaques ; APOE gene ; Dementia ; Neurofibrillary tangles
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: ABSTRACT Alois Alzheimer published two papers on the disease which was named after him by Emil Kraepelin in 1910. Each of these papers contains clinical and pathological data on a patient Alzheimer had seen at the hospital. We have previously reported on the rediscovery of tissue sections from Alzheimer's second published case of Alzheimer disease, Johann F., which probably gave the disease its name (Neurogenetics 1997; 1 : 73–80). Here, we describe the histopathology and APOE genotype of Alois Alzheimer's first patient, Auguste D. As in the case of Johann F., a large number of tissue sections belonging to Alzheimer's laboratory, which was later headed by Spielmeyer, were found among material kept at the Institute of Neuropathology of the University of Munich. As described by Alzheimer in his original report (Allg Zeitschr Psychiatr 1907; 64 : 146–148), there were numerous neurofibrillary tangles and many amyloid plaques, especially in the upper cortical layers of this patient. Yet, there was no microscopic evidence for vascular, i.e., arteriosclerotic, lesions. Interestingly, Alzheimer's histological preparations did not include the hippocampus or entorhinal region. The APOE genotype of this patient was shown to be ε3/ε3 by PCR-based restriction enzyme analysis, indicating that mutational screening of the tissue is feasible. The historical importance of the case of Auguste D. lies in the fact that it marks the beginning of research into Alzheimer disease. In addition, neurofibrillary tangles were first described in this brain.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1433-0407
    Keywords: Schlüsselwörter Magnetresonanztomographie ; Demenz ; Demenz vom Alzheimer-Typ ; MR-Volumetrie ; Signalveränderungen ; Key words Magnetic resonance imaging ; Dementia ; Alzheimer’s disease ; MR-volumetry ; Signalhyperintensity
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary One of the most widely used neuroimaging procedures in Psychiatry and Neurology is magnetic resonance imaging (MRI). MRI has gained the position of a standard investigation in the differential diagnosis of dementia syndromes. In the clinical diagnosis of Alzheimer’s disease (AD) MRI helps to improve the diagnostical accuracy. Recently new MRI-based techniques for performing volumetric measurement of cortical and subcortical structures have been developed. First reports indicate that MRI-based volumetric measurements can be accurate in differentiating AD patients from cognitively normal elderly individuals. These new techniques may be useful adjunct in assessing the clinical diagnosis of AD. Results could also yield insight in the fundamental pathology of the degenerative disease. It is the objective of this chapter to summarize and comment on the significance of MRI in the diagnosis and research of AD. Future directions are outlined, including the use of microscopic MRI, the differentiation of white matter signal hyperintensities and the combined evaluation of stuctural MRI and functional imaging techniques.
    Notes: Zusammenfassung Die Magnetresonanztomographie (MRT) des Gehirns kommt als strukturelles bildgebendes Verfahren in der Psychiatrie und Neurologie zur breiten Anwendung. Bei der Demenz vom Alzheimer-Typ (AD) trägt die MRT zur Verbesserung der klinischen Diagnosestellung im Rahmen der Mehrebenendiagnostik [1] und zur differentialdiagnostischen Abgrenzung anderer mit einem dementiellen Syndrom einhergehender Erkrankungen bei. Neu entwickelte Verfahren der MRT-gestützten Volumetrie kortikaler und subkortikaler Strukturen erwiesen sich als nützlich in der Differenzierung zwischen kognitiv gesunden älteren Probanden und AD-Patienten. Darüber hinaus versprechen sie neue Einsichten in den zeitlichen und strukturellen Verlauf der zerebralen Degeneration. Zusätzlich kann die systematische quantitative Erfassung von Signalveränderungen bei AD-Patienten zur Verbesserung der diagnostischen Genauigkeit beitragen. Es ist die Absicht dieser Arbeit, den Beitrag der MRT zur Diagnostik der AD und zum Verständnis ihrer Pathogenese darzustellen, aber auch die Grenzen dieser Methodik aufzuzeigen. Dabei werden die Veränderungen des gesunden Alterungsprozesses miteinbezogen, die mit Hilfe der MRT-Bildgebung faßbar sind. Zukünftige Perspektiven liegen insbesondere in der Weiterentwicklung der mikroskopischen MRT, der genauen Differenzierung und Klassifikation von Signalveränderungen der weißen Substanz und im kombinierten Einsatz der MRT mit funktionellen bildgebenden Methoden.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-2072
    Keywords: Schizophrenia ; negative symptoms ; clinical trials ; psychiatric status rating scales ; neuroleptics
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract There is little agreement about the methodology of clinical trials of antipsychotic drugs in patients with negative symptoms. A literature review revealed wide variation in experimental design, rating scales and study duration. This reflects differing views as to the definition and response to treatment of negative symptoms. Some degree of standardization would improve comparability of studies and aid the development of new compounds. Patients included in such studies should have displayed negative symptoms for at least 6 months. Depressive symptoms, positive schizophrenic symptoms and extrapyramidal signs may all influence or be confused with negative symptoms and may respond to treatment; they should be at a low level at baseline and should be measured during the study period. Studies should last at least 8 weeks. Several scales are available for measuring negative symptoms and are reviewed; a global impression score should be used additionally.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Electronic Resource
    Electronic Resource
    Springer
    European archives of psychiatry and clinical neuroscience 242 (1993), S. 301-309 
    ISSN: 1433-8491
    Keywords: Neurotic Depression ; Short-term Outcome ; Predictors ; Cognitive Behaviour Therapy ; Antidepressants
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary A study was carried out involving 134 neurotic-depressive inpatients (according to ICD-9) treated with cognitive behaviour therapy and in a subgroup additionally with antidepressants. Using standardized rating instruments, a large set of potential predictor variables was tested. After cross-validation according to the splithalf technique, only very few of these proved to be suitable as predictors for the main outcome criteria. These predictors included certain aspects of social functioning before index admission, intensity of depressive symptoms at admission and the degree of self-evaluated mood disturbances three weeks after admission. Several predictors known from the literature could not be reproduced in this study, demonstrating the well-known instability of most predictor findings. On the other side, the predictor profile of the neurotic-depressive patients was quite similar to that found in endogenous depressives, a result which might — together with other findings, such as the response of neurotic depressives to antidepressants — question the traditional subclassification of functional depressive states into these subgroups.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Electronic Resource
    Electronic Resource
    Springer
    European archives of psychiatry and clinical neuroscience 248 (1998), S. 111-122 
    ISSN: 1433-8491
    Keywords: Key words Alzheimer’s disease ; Dementia ; “Plaque-only” Alzheimer’s disease
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract In 1906, Alzheimer presented the first case of the disease which was later named Alzheimer’s disease by Kraeplin. While the publication on this case in 1907 is only a relatively short communication, Alzheimer published a very comprehensive paper in 1911 in which he discussed the concept of the disease in detail. This publication focusses on the report of a second patient suffering from Alzheimer’s disease, the case of Johann F. The detection of neurohistopathological sections from this patient found among archives at the Institute of Neuropathology of the University of Munich enabled us to reinvestigate this case using modern methods. Neurohistopathologically, the case of Johann F. is “plaque-only” Alzheimer’s disease. There is a controversy in the modern literature as to whether these “plaque-only” cases belong to the modern concept of Alzheimer’s disease. A careful analysis of all pros and contras in the literature led to the conclusion that plaque-only cases are also an integrative part of the modern Alzheimer disease concept.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Electronic Resource
    Electronic Resource
    Springer
    Journal of neural transmission 103 (1996), S. 217-245 
    ISSN: 1435-1463
    Keywords: Brofaromine ; reversible and selective inhibitors of monoamine oxidase (type A) ; pharmacology ; clinical trials
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The antidepressant activity of monoamine oxidase inhibitors has been well established for 30 years. Nevertheless, this group of compounds was handled with great care, mainly because of the interaction potential with tyramine-containing foodstuff. With the discovery of reversible and selective inhibitors of monoamine oxidase type A a renaissance of these compounds has begun. In this paper one of these new substances — brofaromine — will be described in detail. Biochemical and pharmacological aspects will be reviewed, showing that brofaromine is a selective and reversible inhibitor of monoamine oxidase type A with additional serotonin reuptake inhibiting properties. Both mechanisms of action may synergize in the antidepressant effect of the compound. The main results of clinical trials in depression and other indication areas will also be covered. Special attention will be put on the side effect profile.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...